Table 3.
Pharmacotherapy of patients in HF stage C at discharge and at the study visit
| Discharge | Study visit | p | |
|---|---|---|---|
| Beta blocker, n (%) | 210 (93.3) | 191 (84.9) | 0.0021 |
| ACEi/ARB, n (%) | 197 (87.6) | 187 (83.1) | 0.1541 |
| MRA, n (%) | 30 (13.3) | 19 (8.4) | 0.0431 |
| Loop diuretic, n (%) | 66 (29.3) | 72 (32.0) | 0.4511 |
| Thiazide diuretic, n (%) | 35 (15.6) | 42 (18.7) | 0.3821 |
| Glycoside, n (%) | 12 (5.3) | 14 (6.2) | 0.6251 |
N = 225, age 68.1 (9.1) years, males 180 (80%)
ACEi/ARB angiotensin-converting-enzyme inhibitor/angiotensin-receptor blocker, MRA mineralocorticoidreceptor antagonist
1Fisher’s exact test